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Abstract 
Apoptin, the VP3 protein from chicken anaemia virus (CAV), induces tumour cell-
specific cell death and represents a potential future anti-cancer therapeutic. In tumour 
but not in normal cells, Apoptin is phosphorylated and translocates to the nucleus, 
enabling its cytotoxic activity. Recently, the  isozyme of protein kinase C (PKC) 
was shown to phosphorylate Apoptin in multiple myeloma cell lines. However, the 
exact mechanism and nature of interaction between PKC and Apoptin remain 
unclear. Here we investigated the physical and functional link between PKC and 
CAV-Apoptin as well as with the recently identified Apoptin homologue derived 
from human Gyrovirus (HGyV).  
In contrast to HCT116 colorectal cancer cells the normal colon mucosa cell lines 
expressed low levels of PKCI and showed reduced Apoptin activation, as evident by 
cytoplasmic localisation, decreased phosphorylation and lack of cytotoxic activity. 
Co-immunoprecipitation and proximity ligation assay (PLA) studies identified 
binding of both CAV- and HGyV-Apoptin to PKCI in HCT116 cells. Using Apoptin 
deletion constructs the N-terminal domain of Apoptin was found to be required for 
interacting with PKCI. FRET-based PKC activity reporter (CKAR) assays by 
fluorescence lifetime imaging microscopy (FLIM) showed that expression of Apoptin 
in cancer cells but not in normal cells triggers a significant increase in PKC activity.   
Collectively, the results demonstrate a novel cancer specific interplay between 
Apoptin and PKCI. Direct interaction between the two proteins leads to Apoptin-
induced activation of PKC and consequently activated PKCI mediates 
phosphorylation of Apoptin to promote its tumour-specific nuclear translocation and 
cytotoxic function.  
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Introduction 
Apoptin was originally identified as the apoptosis-inducing VP3 protein from chicken 
anaemia virus (CAV), the first member of the Gyrovirus genus [1]. In recent years 
several other viruses resembling the overall organisation of CAV have been 
identified, including the first human Gyrovirus HGyV [2] which contains a VP3 
protein with similar properties as CAV-Apoptin [3]. Importantly, Apoptin has the 
ability to selectively kill various human tumour or transformed cells with little 
cytotoxic effect in normal cells [4-7]. However, the precise cellular mechanisms of 
Apoptin-induced cell death and its mode of tumour selectivity remain unclear [8]. In 
general, Apoptin triggers caspase-dependent cell death via the intrinsic apoptotic 
pathway [9, 10], which occurs independently of p53 but seems to require the activity 
of pro-apoptotic TAp73 isoforms from the p53 family [11, 12]. 
CAV-Apoptin is a small protein of 14 kDa, rich in proline, serine, threonine and basic 
amino acids. It contains a bipartite nuclear localisation signal and a nuclear export 
signal, which facilitate shuttling of the protein between the nucleus and cytoplasm 
[13-15], as well as several potential phosphorylation sites, including threonine-108 
(Thr-108). In tumour cells but not in normal cells Apoptin is phosphorylated on 
Thr-108 [16], which promotes its accumulation in the nucleus of tumour cells whereas 
in normal cells it predominantly localises to the cytoplasm. Both phosphorylation and 
nuclear localisation are important for its pro-apoptotic function in tumour cells [15]. 
The tumour-specific phosphorylation of Apoptin has generated interest in identifying 
cellular kinases with increased activity in tumour cells that might be responsible for 
Apoptin phosphorylation and therefore its tumour-specific activation.  
A number of kinases including cyclin-dependent kinase 2 (Cdk2) have been 
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implicated in Apoptin phosphorylation [17]. Recently, the beta isoform of protein 
kinase C (PKC) was shown to interact with Apoptin and regulate its phosphorylation 
and cytotoxic activity in multiple myeloma cells [18].  
PKC is a family of serine-threonine kinases, comprising at least 13 known isoforms 
that differ in their tissue distribution, subcellular localisation and function [19]. They 
play key roles in the regulation of essential biological processes including 
proliferation, apoptosis and differentiation. Consequently, elevated levels or 
differential activation of PKC isoforms have been linked to various types of cancer 
including colon cancer and leukaemias [20-22]. All isoforms share a similar structure, 
comprising a highly conserved catalytic domain, a regulatory domain and an 
autoinhibitory pseudosubstrate, and can be further subdivided into classical, novel or 
atypical isoforms depending on the composition of regulatory elements [23].  
In unstimulated cells the majority of PKC isoforms are located in the cytosol and 
translocate to the plasma membrane upon stimulation for full activation by lipid co-
activators. Although this event has served as the hallmark for PKC activation, it is 
unclear to what extent translocation to the plasma membrane actually corresponds to 
catalytic activity and substrate phosphorylation. Genetically encodable biosensors 
based on fluorescence resonance energy transfer (FRET) between fluorescent proteins 
provide a novel tool to study signalling processes in cells, such as activation of 
kinases [24] or Rho GTPases [24-26]. FRET refers to a non-radiative type of energy 
transfer between an excited donor fluorophore and an acceptor fluorophore in close 
proximity. This process depletes the donor population in the excited state, reducing 
the fluorescence intensity as well as the fluorescence lifetime of the donor and 
sensitising emission from the acceptor fluorophore. For the detection of PKC activity 
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Violin et al. developed CKAR (C kinase activity reporter) which comprises a PKC 
substrate sequence linked to CFP and YFP as well as the FHA2 phosphothreonine-
binding domain [27]. Activation of PKC triggers a conformational change that 
reduces FRET between the two fluorophores, which can be measured using 
ratiometric imaging of CFP to YFP fluorescence intensity. In contrast to intensity-
based methods for the detection of altered FRET, fluorescence lifetime imaging 
microscopy (FLIM) is independent of fluorophore concentrations and stoichiometry, 
requires only measurement of donor fluorescence and represents a state-of-the-art 
technology to study cellular signalling events [28, 29]. 
Here we show that the activity of Apoptin in human cancer and normal cells derived 
from colon mucosa correlates with respective expression levels of PKCI. Both 
CAV- and HGyV-Apoptin were found to interact and co-localise with PKCI in the 
nucleus of cancer cells. Using a modified CKAR reporter plasmid in a FLIM setup we 
detected Apoptin-induced activation of PKC in cancer cells but not in normal cells. 
Taken together, the data highlight an important role of PKCI for the regulation of 
Apoptin in human cancer cells, which indicates a novel anti-proliferative function for 
PKCI in response to apoptotic stimuli. In addition to elucidating the tumour-specific 
regulation of Apoptin the information obtained could be important for the design of 
future PKC-targeted strategies.  
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Results 
PKCI expression levels correlate with Apoptin activity  
Apoptin phosphorylation and its apoptotic activity are regulated by the PKC isoforms 
I and II in multiple myeloma cell lines [18]. We therefore investigated the link 
between PKC and Apoptin in the human colorectal cancer cell line HCT116, which 
we found to be highly sensitive to Apoptin [11]. HCT116 cells demonstrated 
significantly higher levels of PKCI expression than NCM460 cells derived from 
normal colon mucosa (Fig. 1a) while PKCII levels did not show any marked 
difference (Fig. S1a). 
Western blot analysis of HCT116 and NCM460 cells expressing FLAG-tagged 
Apoptin showed a significantly lower Apoptin phosphorylation in normal cells 
compared to cancer cells by approximately 40% (Fig. 1b). This decreased 
phosphorylation status of Apoptin was associated with a cytoplasmic expression 
pattern of Apoptin in NCM460 cells as shown by fluorescence and confocal 
microscopy, whereas in HCT116 cells Apoptin was exclusively present in the nucleus 
(Fig. 1c, d). In contrast to HCT116 cells, NCM460 cells remained completely 
resistant to Apoptin-induced apoptosis following infection with an adenoviral vector 
to express Apoptin (Fig. 1e). Transient knockdown of PKCI in HCT116 cells to 
nearly undetectable levels was associated with a significant decrease in Apoptin 
phosphorylation by approximately 50% measured as the ratio of phosphorylated 
Apoptin (P-Apoptin) to total GFP-Apoptin (Fig. 1f). 
The differential activity and expression of Apoptin was confirmed using another 
normal colon mucosa cell line, NCM356, with significantly lower expression levels of 
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PKCI (Fig. S1a-d). Overall the results suggest a correlation between PKCI 
expression levels and the tumour-specific activity of Apoptin, indicated by its 
phosphorylation, nuclear localisation and cytotoxicity. 
Apoptin interacts with PKCI in the nucleus of colon cancer cells 
A number of cellular proteins have been identified as Apoptin binding partners and 
regulators of its function and tumour cell-specific cytotoxicity. To test whether 
CAV-Apoptin and its newly discovered homologue HGyV-Apoptin can directly bind 
to PKCI in colon cancer cells, HCT116 cells were co-transfected with HA-tagged 
PKCI and plasmids expressing FLAG-tagged Apoptin. Both CAV- and 
HGyV-FLAG-Apoptin were present in immunocomplexes pulled down from total cell 
extracts using anti-FLAG antibodies (Fig. 2a). As expected from their respective 
amino acid sequences, HGyV-Apoptin was detected at a slightly higher molecular 
weight than CAV-Apoptin [3]. Similarly, the reciprocal immunoprecipitation using 
anti-HA antibodies confirmed binding of Apoptin to PKCI in HCT116 cells (data 
not shown).  
The interaction between Apoptin and endogenous PKCI was further analysed using 
the proximity ligation assay (PLA) which allows the direct detection and localisation 
of protein interactions in situ [30]. Staining of HCT116 cells transfected with 
FLAG-Apoptin using antibodies against Apoptin and FLAG served as a positive 
control for all PLA experiments (Fig. 2b). To detect binding of Apoptin to PKCI, 
HCT116 cells were transfected with CAV- or HGyV-FLAG-Apoptin or the pcDNA3 
control plasmid and stained with antibodies directed against FLAG and PKCI, 
followed by PLA analysis. Red fluorescent PLA signals, indicating a site of protein 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
interaction, were detected in cells expressing both types of Apoptin but not cells 
transfected with the control vector (Fig. 2c). Corresponding to the expression pattern 
of Apoptin these were predominantly localised in the nucleus, indicating nuclear 
translocation of PKCI in response to Apoptin expression. Quantification of positive 
PLA foci showed a significantly increased number of signals in Apoptin-expressing 
cells compared to control cells (Fig. 2c). The clear interaction between Apoptin and 
PKCI observed by PLA is unlikely to be affected by cell death as no significant 
induction of apoptosis was observed at the same time point following transfection of 
Apoptin plasmids (data not shown). 
We next investigated the importance of the N-terminal part of Apoptin for binding to 
PKCβ. This region contains a leucine-rich stretch and has been implicated in 
interaction of Apoptin with other cellular proteins. In contrast to cells expressing full-
length GFP-Apoptin, HCT116 cells transfected with an Apoptin mutant lacking 
amino acids 1 to 73 showed no significant increase in the total number of PLA signals 
compared to the GFP control (Fig. 2d). This data suggests that the C-terminal half of 
Apoptin alone is not sufficient to mediate binding to PKCI and that interacting 
regions are located within the N-terminus. Additional Apoptin mutants need to be 
tested in order to precisely map the region/s required for interacting with PKCI. 
FRET-based measurements of PKC activity 
PKC-mediated Apoptin phosphorylation and Apoptin-induced translocation of 
PKC to the nucleus suggest a novel regulatory loop between Apoptin and PKC 
activities. To monitor PKC activity we employed a modified version of the PKC 
activity reporter CKAR [27] which consists of the two fluorophores GFP and RFP 
linked by a PKC substrate sequence and the FHA2 phosphothreonine-binding domain 
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(Fig. 3a). As illustrated, PKC-induced phosphorylation of the substrate triggers a 
conformational change, resulting in a decrease of FRET from GFP to RFP and 
consequently an increase in the fluorescence intensity and lifetime of the donor 
fluorophore GFP. We detected alterations in FRET by measuring the two-photon 
excited fluorescence lifetime  of GFP using a time-correlated single-photon counting 
system (TCSPC) established for FLIM [31]. Mapping of GFP lifetimes across single 
cells expressing CKAR allowed for the visualisation of PKC activity and calculation 
of average GFP lifetimes (Fig. 3b). Comparison of a number of cells transfected with 
the reporter plasmid to cells expressing only the donor fluorophore GFP showed a 
clear decrease of average GFP lifetimes from 2.14 to 1.86 ns, indicating FRET 
between GFP and RFP with a FRET efficiency of 13.3% (Fig. 3b). 
The ability of CKAR used in this TCSPC/FLIM setup to measure alterations in PKC 
activity was tested in HCT116 cells transfected with CKAR followed by treatment 
with the PKC agonist TPA or Gö6976, an inhibitor of classical PKC isoforms. As 
shown on representative FLIM images TPA treatment, as expected, triggered a shift 
to higher GFP lifetimes, indicating activation of PKC, whereas GFP lifetimes were 
reduced following treatment with Gö6976 (Fig. 3c). This was reflected in a 
corresponding increase or decrease of average GFP lifetimes compared to untreated 
cells, suggesting that CKAR is suitable for the detection of changes in PKC activity 
following pharmacological modulation. 
Apoptin expression induces cancer specific PKC activation 
To investigate the effect of Apoptin on PKC activity, HCT116 cells were transfected 
with CKAR followed by infection with an adenoviral vector to express Apoptin 
(Ad-Apoptin). Apoptin expression was detected by Western blot analysis after 
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5 hours and further increased until 16 hours post-infection with Ad-Apoptin (Fig. 4a). 
Phosphorylated Apoptin was detectable after 8 and 16 hours, suggesting activity of 
the Apoptin kinase before or at that time point. As shown on representative FLIM 
images Apoptin expression was associated with a time-dependent increase in PKC 
activity as indicated by a shift to higher GFP lifetimes in Apoptin-treated cells 
(Fig. 4b). Measurement of average GFP lifetimes confirmed a significant increase in 
PKC activity at 8 and 16 hours post-infection similar to control treatment with TPA. 
A later drop of GFP lifetimes to basal levels might be due to apoptosis as a similar 
reduction of PKC activity was observed in cisplatin-treated cells (data not shown). 
These results suggest Apoptin-induced activation of PKC, correlating with the 
expression and phosphorylation levels of Apoptin at the respective stage in human 
cancer cells. 
Apoptin phosphorylation and therefore activity of the Apoptin kinase represents an 
important aspect of the tumour cell-specific cytotoxic function of Apoptin. We 
therefore investigated whether Apoptin expression in normal colon mucosa cells with 
lower expression levels of PKCI (Fig. 1a, Fig. S1a) would trigger activation of PKC 
as observed in cancer cells. In contrast to HCT116 cells, which showed a significant 
increase in PKC activity following infection with Ad-Apoptin, PKC activation 
remained unaltered in normal NCM356 cells at any time point (Fig. 4c). Similarly, 
compared to HCT116 cells Apoptin only triggered a minor increase in PKC activity in 
normal NCM460 cells (Fig. 4d), suggesting that this differential effect of Apoptin on 
the activation status of PKC is not cell type-specific. Apoptin-induced PKC activation 
therefore seems to occur predominantly in tumour cells but not in normal cells and 
might depend on the presence of PKCI. 
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Discussion 
Specific killing of tumour cells while minimising damage to normal tissues remains a 
major challenge in the development of effective anti-cancer agents. In recent years, 
several cellular or viral proteins that selectively induce cell death in cancer cells have 
been identified, including Apoptin which was originally discovered as the 
apoptosis-inducing protein from CAV [8]. Gaining further understanding of their 
regulation and cellular targets is essential for their development into future therapeutic 
agents as well as the identification of novel tumour-specific targets and processes. 
In this study we investigated the physical and functional interaction between Apoptin 
and PKC. The PKC signalling pathway has predominantly been associated with 
survival, proliferation and inhibition of apoptosis and is therefore an important target 
for the development of anti-cancer agents.  
Tumour cell-specific phosphorylation of Apoptin on Thr-108 by a cellular kinase 
represents an important step for its accumulation in the nucleus and cytotoxic activity 
[16] and PKC was identified as a potential Apoptin kinase, but so far only in 
multiple myeloma cells [18]. Several cancer types, including multiple myeloma, show 
increased expression or activity of PKC, suggesting that PKC might represent a 
tumour-specific target responsible for sensitising cells to Apoptin [20-22].  
We therefore investigated the dynamics of the interplay between Apoptin and PKCI 
in HCT116 cells, a colorectal cancer cell line expressing high levels of PKCI and 
displaying high sensitivity to Apoptin. Co-immunoprecipitation and PLA studies 
convincingly showed direct binding and co-localisation of Apoptin and PKCI. This 
interaction seemed to require the N-terminal region of Apoptin which has been shown 
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to be involved in both binding of Apoptin to other cellular proteins [32-34] as well as 
Apoptin multimerisation [35]. Importantly, interaction with Apoptin triggered nuclear 
translocation of PKCI; to our knowledge this is a novel phenomenon in respect to 
PKCI activity. The importance of this nuclear localisation on the activity of PKCI 
is currently unclear, however it may cause changes to PKCI accessibility for its 
substrates and/or its function [18]. Notably, Apoptin has been shown to trigger 
nuclear accumulation of the related kinase Akt, switching its pro-survival to pro-
apoptotic activity in prostate cancer cells [36].  
In contrast to HCT116 cells, two cell lines derived from normal colon mucosa were 
found to express almost undetectable levels of PKCI. Increased expression levels of 
PKCI in HCT116 cells correlated with enhanced activation of Apoptin, 
demonstrated by increased expression and phosphorylation levels of Apoptin, its 
translocation to the nucleus as well as induction of apoptosis in cancer cells while 
normal colon mucosa cells remained resistant to Apoptin expression. Knockdown of 
PKCI in HCT116 cells reduced Apoptin phosphorylation, albeit not completely 
which might be due to residual Apoptin phosphorylation by other regulatory kinases 
such as PKCII or Cdk2.  
Interestingly, HGyV-Apoptin, a recently identified VP3 homologue derived from the 
first human Gyrovirus HGyV [2, 3], was also shown to interact with PKCI. An 
online kinase prediction assay of the HGyV-Apoptin amino acid sequence 
(http://www.cbs.dtu.dk/services/NetPhos) revealed several potential phosphorylation 
sites matching the PKC consensus motif (S/TXK/R or S/TXXK/R) including Thr-111 
which, like Thr-108 of CAV-Apoptin, is adjacent to a putative NES within the 
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respective protein. This suggests a similar mode of tumour-specific regulation of 
HGyV-Apoptin by PKCI-mediated phosphorylation as identified for CAV-Apoptin. 
Using CKAR, a FRET-based biosensor for PKC activation, we showed a transient 
increase in PKC activity following Apoptin expression in HCT116 cells similar to 
treatment with known PKC activators. The demonstrated increase in PKC activity 
correlated with the presence of phosphorylated Apoptin, suggesting a link between 
Apoptin expression, PKC activation and Apoptin phosphorylation. In contrast to 
HCT116 cancer cells, normal colon mucosa cell lines displayed significantly reduced 
and delayed activation of PKC following Apoptin expression. These data support an 
important role for PKC in the tumour cell-specific regulation of Apoptin. 
Despite the biosensor’s lack of discrimination between various classical and novel 
PKC isoforms [37], the reduced PKC activation in normal colon mucosa cells lacking 
PKCI indicates specific activation of PKCI by Apoptin. However, a potential 
involvement of other PKC isoforms, including PKCII or PKC, cannot be excluded 
and should be further investigated. Importantly, PKC is generally considered to be a 
pro-apoptotic PKC isoform that is cleaved and activated in response to many pro-
apoptotic stimuli [38] including Apoptin expression and might represent a link 
between Apoptin-induced PKC activation and induction of caspase-dependent 
apoptosis [18].  
It remains to be determined how the presence of Apoptin triggers activation of PKC. 
Using in vitro kinase assays we have previously shown PKC-mediated Apoptin 
phosphorylation after incubation with PKC alone without any additional PKC 
activators in the reaction [18], suggesting that the presence of Apoptin alone is 
sufficient to activate PKC.  
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Allosteric activation of PKCII has been suggested to involve exposure of 
arginine-19 to proteolysis, which is shielded by a cluster of acidic residues under 
non-stimulated conditions [39]. Apoptin is rich in basic amino acids, which could 
potentially bind to these acidic residues on PKC to expose Arg-19 and thereby 
trigger PKC activation. 
In conclusion, this study has established an important tumour-specific link between 
Apoptin and PKCI in colon cancer cells. Remarkably, this interaction induces not 
only PKC-dependent phosphorylation of Apoptin but also nuclear translocation and 
activation of PKC. In addition to phosphorylating Apoptin, modulation of PKC 
activity by Apoptin could trigger other yet unknown cellular pathways shifting the 
balance from proliferation to apoptosis. 
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Materials and Methods 
Cell Lines and Reagents 
HCT116 cells were obtained from ATCC and maintained in McCoy’s 5A medium 
supplemented with 10% foetal bovine serum, 50 µg/ml streptomycin and 100 µg/ml 
penicillin (PAA Laboratories). NCM356 and NCM460 cells were purchased from 
INCELL Corporation. Cisplatin was obtained from the Guy’s Hospital Pharmacy. 
Adenoviral vectors for the expression of Apoptin (Ad-Apoptin) or GFP (Ad-GFP) 
were generated as described previously [40]. For viral infections, virus stocks were 
diluted in culture medium to achieve the desired MOI (multiplicity of infection) and 
added to the cells. 
Transient Transfection 
pCAV-FLAG-AP for the expression of CAV-FLAG-Apoptin was obtained from Dr. 
Jose Teodoro (Goodman Cancer Research Centre, Montreal, Canada), plasmids for 
full-length or truncated GFP-Apoptin (pEPI-GFP-Apoptin 1-121 or 74-121) were 
provided by Dr. Gualtiero Alvisi (Monash University, Clayton, Australia). The 
expression vector for HGyV-FLAG-Apoptin (pHGyV-FLAG-AP) was generated as 
described previously [3]. pHA-PKCI was obtained from Professor Alexandra 
Newton (University of California, San Diego, CA). pGFP/RFP CKAR was modified 
from the original reporter construct pCFP/YFP CKAR [27] by Dr. Melanie Keppler 
(King’s College, London). Control vectors used were pcDNA3.1 and peGFP-C1 (Life 
Technologies).  
HCT116 cells were transiently transfected using X-tremeGENE HP transfection 
reagent according to the manufacturer’s protocol (Roche Applied Science). In short, a 
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mix of plasmid DNA and transfection reagent was prepared in OptiMEM reduced-
serum medium (Life Technologies) and added dropwise to the cells after incubation 
for 20 min at room temperature. 
Transient siRNA Knockdown 
siGENOME Human PRKCB siRNA SMARTpool targeting PKCI (targeting 
sequences GAACCAAGGUCCCGGAAGA, GGAUGAAACUGACCGAUUU, 
CCAAGUCUAUGUCCAAGGA, AGAGUAAGGGCAUCAUUUA) and GAPDH 
control siRNA were obtained from Dharmacon (GE Healthcare). Cells were 
transfected with siRNAs using the X-tremeGENE siRNA transfection reagent as 
recommended by the manufacturer (Roche Applied Science). In short, siRNA and 
transfection reagent were prepared separately in OptiMEM reduced- serum medium 
(Life Technologies), mixed carefully and added dropwise to the cells after incubation 
for 20 min at room temperature. 
Lentivirus production 
Lentiviral expression constructs for GFP (Lenti-GFP) or CAV-GFP-Apoptin 
(Lenti-GFP-AP) were constructed as previously described [18]. Lenti-FLAG-AP for 
the expression of CAV-FLAG-Apoptin was generated by insertion of the 
FLAG-Apoptin gene from pCAV-FLAG-AP into the lentiviral backbone used for 
Lenti-GFP. 
Lentiviruses were produced in HEK293T cells transfected with the second- 
generation packaging plasmid pCMVΔ8.91 and plasmid pMDG encoding 
VSV-G-pseudotyped envelope as well as the construct of interest by calcium 
phosphate precipitation. The virus-containing supernatant was harvested at 24 and 48 
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hours post-transfection, put through a 0.45 μm filter, concentrated by centrifugation 
for 6 hours at 13,000 x g and stored at -70°C. For infection lentiviral stocks were 
diluted in a minimal amount of medium supplemented with 5 µg/ml polybrene (Santa 
Cruz Biotechnology) and added to target cells. 
Flow cytometry 
Cells were cultured on 12-well plates at a density of 1 x 10
5
 cells per well and
infected the next day. Cells were collected after 40 hours after by trypsinisation and 
washing in PBS. Apoptosis was quantified by staining with Annexin V-APC 
(BD Biosciences) and propidium iodide (PI, Sigma-Aldrich). Data was acquired on a 
BD FACSCantoII flow cytometer (BD Biosciences) and analysed using FlowJo 
software (Tree Star, Inc.) 
Immunoprecipitation 
Cells were seeded on 6-well plates at a density of 2 x 10
5
 cells per well and
transfected the next day as indicated. At 2 days post-transfection cells were collected 
by scraping and washing with cold PBS and centrifuged for 15 min at 16,000 x g. The 
obtained cell pellet was resuspended in 250 μl to 500 μl radioimmunoprecipiation 
assay buffer (Cell Signalling), sonicated and incubated for 1 hour on ice. After 
centrifugation at 4°C and 16,000 x g for 10 min the supernatant was transferred to a 
new tube and incubated with 2 μg of anti-HA or anti-FLAG antibody for 30 min 
under agitation at 4°C. 20 μl of washed Bio-Adembeads PAG (Ademtech) was added 
and incubated with the sample for 3 hours at 4°C. Using a magnetic rack, beads were 
washed and isolated from the solution and proteins were removed from the beads by 
resuspending in Laemmli sample buffer and boiling for 5 min at 95°C. 
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Western blot analysis 
Cells were cultured on 6-well plates at a density of 2 x 10
5
 cells per well and treated 
the next day. Cells were collected by trypsinisation, washed in PBS and re-suspended 
in lysis buffer (2 mM MgCl2, 25 mM HEPES, 2 mM EGTA, 0.1% Triton X-100) 
supplemented with protease inhibitors. Following 30 min incubation on ice, protein 
lysates were obtained by centrifugation for 15 min at 16,000 x g. 40 to 60 µg of 
protein was used for further SDS-PAGE and transfer of proteins to nitrocellulose 
membranes (Sigma-Aldrich). Membranes were incubated with specific primary and 
secondary antibodies as indicated and developed using an enhanced 
chemiluminescent system.  
Antibodies used for immunoblotting were: -actin, Tubulin, FLAG (Sigma-Aldrich), 
PKCI, PKCII (Santa Cruz Biotechnology), GFP and HA (Cell Signalling).  
Antibodies directed against total or Thr-108-phosphorylated Apoptin (P-Apoptin) 
were obtained as described previously [18]. Secondary HRP-coupled anti-rabbit and 
anti-mouse antibodies were obtained from GE Healthcare and Sigma-Aldrich, 
respectively. The relative expression or phosphorylation levels of proteins were 
determined using ImageJ software. 
Immunofluorescence 
Cells were grown on Falcon 8-chamber culture slides (BD Biosciences) at a density of 
2 x 10
4
 to 3 x 10
4
 cells per well and transfected the next day. After 2 days cells were 
washed in PBS, fixed in 4% paraformaldehyde for 10 min and permeabilised with 
0.2% Triton X-100 for 10 min. After permeabilisation cells were washed in PBS, 
blocked using 3% BSA in PBS-T for 30 min and incubated with a primary anti-FLAG 
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antibody for 90 min and a secondary FITC-conjugated anti-mouse antibody (Sigma-
Aldrich) for 1 hour. Cells were washed between incubations in PBS and all steps were 
carried out at 37°C. Cells were mounted in Vectashield mounting medium containing 
DAPI (Vector Laboratories) to stain nuclei. Images were acquired on an Olympus 
BX61 automated fluorescence microscope or an A1R Si Confocal System and Eclipse 
Ti-E Inverted Microscope (Nikon) for confocal microscopy. 
Proximity Ligation Assay (PLA) 
Cells were seeded in Falcon 8-chamber culture slides (BD Biosciences) at a density of 
3 x 10
4
 cells per well and transfected the next day. After 2 days cells were washed in 
PBS, fixed in 4% paraformaldehyde for 10 min, washed again and permeabilised with 
0.2% Triton X-100 for 10 min. After permeabilisation cells were blocked in blocking 
solution for 30 min and then incubated with the indicated primary antibodies for 2 
hours at 37°C in a humidity chamber. All further steps were carried out according to 
the manufacturer’s instructions (Duolink In Situ kit, Olink) in a reaction volume of 
80 μl per well with three washing steps in Buffer A between incubations. Briefly, 
cells were incubated with PLA probes for 1 hour followed by a ligation reaction for 
30 min and incubation with an amplification mix for 100 min. After mounting in 
DAPI-containing mounting medium images were acquired on the Olympus BX61 
automated fluorescence microscope using Cell^F software (Olympus) and analysed 
using Blobfinder software (Olink) to automatically detect and quantify positive PLA 
signals. 
Fluorescence Lifetime Imaging Microscopy (FLIM) 
Cells were seeded on sterile coverslips in 24-well plates at a low density and 24 hours 
later transfected with pGFP/RFP CKAR or peGFP-C1. The next day cells were 
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infected with Ad-Apoptin at an MOI of 10 to express Apoptin for 2 up to 24 hours 
before fixation in 4% paraformaldehyde for 10 min. Control cells were treated with 
200 nM TPA (12-O-Tetradecanoylphorbol-13-Acetate, Cell Signalling) for 30 min or 
50 nM Gö6976 (Calbiochem) for 120 min. To reduce autofluorescence fixed cells 
were treated with 1 mg/ml sodium borohydride for 5 min and mounted on slides in 
8 μl FluorSave mounting medium (Calbiochem). 
Time-domain FLIM was performed using a home-built two-photon laser-scanning 
microscope based on the modified Nikon Eclipse Ti-E inverted microscope. A mode- 
locked Ti:Sapphire laser (Coherent, Chameleon Vision) with repetition rate of 
80 MHz and pulse width of ~140 fs was tuned to 890 nm providing a photoexcitation 
source for GFP. GFP fluorescence (500/40 nm bandpass) was detected with a 
40x/1.3NA objective lens and a hybrid photo multiplier tube (PMT, HPM-100) in 
conjunction with a time-correlated single-photon counting (TCSPC, SCP-150) card 
(both from Becker & Hickl). Images were acquired at 256 x 256 pixels with peak 
photon counting rates kept below 10
7
 photons per second to avoid pulse pile-up. The 
GFP fluorescence lifetime τ was calculated by fitting bi-exponential fluorescence 
decay models to the images using TRI2 software (Paul Barber, University of Oxford). 
Output files were analysed to produce a distribution of the GFP lifetime across the 
cells and calculation of average donor lifetimes in single cells. 
Statistical Analysis 
Statistical analysis of results obtained from at least three independent experiments 
was performed using GraphPad Prism 6 software and one- or two-way analysis of 
variance (ANOVA) or two-tailed Student’s t test as appropriate and indicated.  
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Supplementary Material 
Fig. S1 Correlation of PKCI Levels and Apoptin Activity in HCT116 and NCM356 
Cells 
Legends to Figures 
Fig. 1 Correlation of PKCI Levels and Apoptin Activity in Colon Cancer and 
Normal Cells 
(a) PKCI expression in HCT116 and NCM460 cells was investigated by Western 
blot analysis of total cell lysates, showing results from 2 separate cultures. Bars 
represent PKCI expression normalised to -Actin; error bars indicate SEM (n = 7). 
Statistical significance was determined by unpaired two-tailed Student’s t test 
(*** P < 0.001). (b) HCT116 and NCM460 cells were infected with Lenti-GFP (GFP) 
or Lenti-CAV-FLAG-AP (Apo) at an MOI of 5 for 2 days. Total cell lysates were 
analysed by immunoblotting with the indicated antibodies; blots were cut and 
combined at the indicated line. Bars represent ratios of phosphorylated Apoptin 
(P-Apoptin) to FLAG-Apoptin; error bars indicate SEM (n = 4). Statistical 
significance was determined by unpaired two-tailed Student’s t test (** P < 0.01). 
(c/d) HCT116 and NCM460 cells were transfected with CAV-FLAG-AP, fixed after 
24 hours and stained with a primary mouse anti-FLAG and secondary FITC-
conjugated anti-mouse antibody and DAPI for detection of nuclei. Representative 
widefield (c, original magnification 60x, bar = 10 μm) and confocal (d, original 
magnification 100x, bar = 20 μm) fluorescence images are shown. Bars represent the 
percentage of Apoptin-expressing cells with nuclear localisation of Apoptin; error 
bars indicate SEM (n = 3). Statistical significance was determined by unpaired two-
tailed Student’s t test (*** P < 0.001). (e) HCT116 and NCM460 cells were infected 
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with Ad-GFP or Ad-Apoptin at an MOI of 10 for 40 hours before cell death detection 
by Annexin V/PI staining and FACS analysis. Bars represent the mean percentage of 
Annexin V positive cells; error bars indicate SEM (n = 4). Statistical significance was 
determined by two-way ANOVA (*** P < 0.001). (f) HCT116 cells were transfected 
with PKCI or GAPDH control siRNA and infected 24 hours later with Lenti-CAV-
GFP-AP at an MOI of 5. Total cell lysates were collected after 2 days for Western 
blot analysis with the indicated antibodies. Bars represent ratios of phosphorylated 
Apoptin (P-Apoptin) to total GFP-Apoptin; error bars indicate SEM (n = 3). 
Statistical significance was determined by one-way ANOVA (* P < 0.05, ns P > 
0.05). 
 
Fig. 2 Interaction and Co-localisation of CAV-Apoptin and HGyV-Apoptin with 
PKCI in the Nucleus of Cancer Cells 
(a) HCT116 cells were co-transfected with CAV-FLAG-AP (CAV) or HGyV-FLAG-
AP (HGyV) and HA-PKCI. Immunocomplexes pulled down with anti-FLAG 
antibodies and total cell lysates prepared in RIPA buffer at 2 days post-transfection 
were subjected to Western blot analysis with the indicated antibodies. (b) HCT116 
cells were transfected with CAV-FLAG-AP or pcDNA3 followed by PLA staining 
using anti-FLAG and anti-P-Apoptin antibodies and counterstaining of nuclei with 
DAPI. Representative PLA images are shown (original magnification 60x, 
bar = 10 µm).  (c) HCT116 cells were transfected with CAV-FLAG-AP, HGyV-
FLAG-AP or pcDNA3 and analysed by PLA at 2 days post-transfection using anti-
FLAG and anti-PKCI antibodies. Representative images indicating nuclei 
counterstained with DAPI and PLA signals are shown (original magnification 60x, 
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bar = 10 μm). Bars represent average number of PLA foci per cell calculated from at 
least 100 cells (excluding cells with 0 signals); error bars indicate SEM (n = 3). 
Statistical significance was determined by one-way ANOVA (* P < 0.05, ** P < 
0.01). (d) HCT116 cells were transfected with peGFP-C1 or the indicated pEPI-GFP-
Apoptin plasmids and analysed by PLA using anti-GFP and anti-PKCI antibodies at 
2 days post-transfection. Representative images indicating nuclei counterstained with 
DAPI, PLA signals or GFP expression are shown (original magnification 60x, 
bar = 10 μm). Bars represent average number of PLA foci per cell, localised to either 
the nucleus or the cytoplasm, calculated from at least 100 GFP-expressing cells; error 
bars indicate SEM (n = 3). Statistical significance was determined by one-way 
ANOVA (* P < 0.05, ns P > 0.05). 
 
Fig. 3 Measurement of PKC activity by FRET/FLIM using CKAR 
(a) Structure of the PKC activity reporter CKAR, comprising GFP and RFP linked by 
a PKC substrate sequence and the FHA2 phosphothreonine-binding domain of 
Rad53p. PKC-induced phosphorylation of the substrate sequence triggers a 
conformational change, resulting in reduced FRET measured as an increase of the 
fluorescence lifetime  of the donor GFP (adapted from [27]). (b) HCT116 cells were 
transfected with pGFP/RFP CKAR or peGFP-C1 and fixed for FLIM analysis the 
following day. A representative FLIM image of a single cell, indicating the 
distribution of GFP lifetime () is shown (bar = 10 μm). Each symbol represents the 
average  of a single cell; lines indicate the mean value of  for the entire sample. (c) 
HCT116 cells were transfected with pGFP/RFP CKAR and treated the following day 
with 200 nM TPA for 30 min or 50 nM Gö6976 for 120 min before fixing for FLIM 
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analysis. Representative FLIM images indicating  are shown (bar = 10 μm). Bars 
represent changes in average compared to untreated cells, corresponding to PKC 
activity, from at least 15 cells per sample; error bars indicate SEM (n = 5). Statistical 
significance was determined by one-way ANOVA (* P < 0.05, *** P < 0.001).  
 
Fig. 4 Apoptin-induced Activation of PKC Isoforms in Colon Cancer Cells but 
not Normal Cells 
(a) HCT116 cells were infected with Ad-Apoptin at an MOI of 10 and cell lysates 
were collected at the indicated time points for Western blot analysis. Blots were cut 
and combined at the indicated line. (b) CKAR-expressing HCT116 cells were 
infected with Ad-Apoptin at an MOI of 10 before fixing for FLIM analysis at the 
indicated time points. Representative FLIM images indicating  are shown 
(bar = 10 μm). Bars represent changes in average compared to untreated cells 
calculated from at least 15 cells per sample; error bars indicate SEM (n = 3 for 2h/5h, 
n = 5 for 8h/16h/24h). Statistical significance was determined by one-way ANOVA 
(* P < 0.05, *** P < 0.001). (c/d) HCT116 and NCM356 (c) or NCM460 (d) cells 
were transfected with pGFP/RFP CKAR and infected the following day with Ad-
Apoptin at an MOI of 10 for 8 or 16 hours before fixing for FLIM analysis. Bars 
represent changes in average compared to untreated cells calculated from at least 10 
cells per sample; error bars indicate SEM (n = 3). Statistical significance was 
determined by two-way ANOVA (** P < 0.01).  
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Fig. S1 Correlation of PKCI Levels and Apoptin Activity in HCT116 and 
NCM356 Cells 
(a) PKCI and PKCII expression levels in HCT116, NCM356 and NCM460 cells 
were determined by Western blot analysis. (b) HCT116 and NCM356 cells were 
infected with Lenti-GFP (GFP) or Lenti-CAV-FLAG-AP (Apo) at an MOI of 5. Total 
cell lysates were collected after 2 days for Western blot analysis with the indicated 
antibodies; blots were cut and combined at the indicated line. (c) HCT116 and 
NCM356 cells were transfected with CAV-FLAG-AP, fixed after 24 hours and 
stained with a primary mouse anti-FLAG and secondary FITC-conjugated anti-mouse 
antibody. Nuclei were detected by counterstaining with DAPI. Representative 
fluorescence images are shown (magnification 60x, bar = 10 µm). (d) HCT116 and 
NCM356 cells were infected with Ad-GFP or Ad-Apoptin at an MOI of 10 and 
collected at 40 hours post-infection for cell death detection by Annexin V/PI staining 
and FACS analysis. Bars represent the percentage of Annexin V positive cells; error 
bars indicate SEM (n = 4). Statistical significance was determined by two-way 
ANOVA (*** P < 0.001). 
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